Ion channels in death and differentiation of prostate cancer cells

Cell Death and Differentiation

Volumn 14, Issue 7, 2007, Pages 1295-1304

  Prevarskaya, N ^a   Skryma, R ^a   Bidaux, G ^a   Flourakis, M ^a   Shuba, Y ^b  

^a Université des Sciences et Technologies de Lille   (France)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM ION; CLUSTERIN; DEQUALINIUM; FLUNARIZINE; GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; ION CHANNEL; MESSENGER RNA; PHOSPHOLIPASE C; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; POTASSIUM ION; PROTEIN BCL 2; SURVIVIN; TRANSCRIPTION FACTOR NFAT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; UNINDEXED DRUG; VANILLOID RECEPTOR; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CALCIUM TRANSPORT; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL VOLUME; DISEASE MARKER; DOWN REGULATION; DRUG TARGETING; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; ION CHANNELS; IONS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS;

EID: 34250755405     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402162     Document Type: Review

References (92)

1. Lang F, Foller M, Lang KS, Lang PA, Ritter M, Gulbins E et al. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol 2005; 205: 147-157.
2. Razik MA, Cidlowski JA. Molecular interplay between ion channels and the regulation of apoptosis. Biol Res 2002; 35: 203-207.
3. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines - part 1. J Urol 2005; 173: 342-359.
4. + channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch 2004; 448: 274-286.
5. + channels: An essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 2004; 286: L49-L67.
6. Yu SP. Regulation and critical role of potassium homeostasis in apoptosis. Prog Neurobiol 2003; 70: 363-386.
7. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, Rubio ME et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer 2006; 5: 41.
8. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stuhmer W. Role of voltage-gated potassium channels in cancer. J Membr Biol 2005; 205: 115-124.
9. Pardo LA, del Camino D, Sanchez A, Alves F, Bruggemann A, Beckh S et al. Oncogenic potential of EAG K(+) channels. EMBO J 1999; 18: 5540-5547.
10. + channel gating. Mol Pharmacol 2001; 59: 1376-1387.
11. Skryma R, Van Coppenolle F, Dufy-Barbe L, Dufy B, Prevarskaya N. Characterization of Ca(2+)-inhibited potassium channels in the LNCaP human prostate cancer cell line. Receptors Channels 1999; 6: 241-253.
12. Skryma RN, Prevarskaya NB, Dufy-Barbe L, Odessa MF, Audin J, Dufy B. Potassium conductance in the androgen-sensitive prostate cancer cell line LNCaP: Involvement in cell proliferation. Prostate 1997; 33: 112-122.
13. Laniado ME, Fraser SP, Djamgoz MB. Voltage-gated K(+) channel activity in human prostate cancer cell lines of markedly different metastatic potential: Distinguishing characteristics of PC-3 and LNCaP cells. Prostate 2001; 46: 262-274.
14. Abdul M, Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 2002; 186: 99-105.
15. Fraser SP, Grimes JA, Diss JK, Stewart D, Dolly JO, Djamgoz MB. Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: Electrophysiological, pharmacological and molecular characterisation. Pflugers Arch 2003; 446: 559-571.
16. Ouadid-Ahidouch H, Van Coppenolle F, Le Bourhis X, Belhaj A, Prevarskaya N. Potassium channels in rat prostate epithelial cells. FEBS Lett 1999; 459: 15-21.
17. Anderson JD, Hansen TP, Lenkowski PW, Walls AM, Choudhury IM, Schenck HA et al. Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. Mol Cancer Ther 2003; 2: 1149-1154.
18. Wible BA, Wang L, Kuryshev YA, Basu A, Haldar S, Brown AM. Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem 2002; 277 17852-17862.
19. Gessner G, Schonherr K, Soom M, Hansel A, Asim M, Baniahmad A et al. BKCa channels activating at resting potential without calcium in LNCaP prostate cancer cells. J Membr Biol 2005; 208: 229-240.
20. Abdul M, Hoosein N. Voltage-gated sodium ion channels in prostate cancer: Expression and activity. Anticancer Res 2002; 22: 1727-1730.
21. + channels confer invasive properties on human prostate cancer calls. Pflugers Arch 2004; 447: 908-914.
22. Diss JK, Archer SN, Hirano J, Fraser SP, Djamgoz MB. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate 2001; 48: 165-178.
23. Diss JK, Stewart D, Pani F, Foster CS, Walker MM, Patel A et al. A potential novel marker for human prostate cancer: Voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis 2005; 8: 266-273.
24. Fraser SP, Salvador V, Manning EA, Mizal J, Altun S, Raza M et al. Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. Lateral motility. J Cell Physiol 2003; 195: 479-487.
25. Mycielska ME, Fraser SP, Szatkowski M, Djamgoz MB. Contribution of functional voltage-gated Na+ channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: II. Secretory membrane activity. J Cell Physiol 2003; 195: 461-469.
26. + channel activity in human prostate cancer cells: Independent modulation of in vitro motility. Prostate Cancer Prostatic Dis 2006; 9: 399-406.
27. Rosenthal E, Shapiro E, Lepor H. Characterization of 1,4, dihydropyridine calcium channel binding sites in the human prostate. J Urol 1990; 144: 1539-1542.
28. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119-130.
29. Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 1990; 17: 175-187.
30. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503-519.
31. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: An update. Prostate Suppl 1998; 8: 74-79.
32. Kim JH, Shin SY, Yun SS, Kim TJ, Oh SJ, Kim KM et al. Voltage-dependent ion channel currents in putative neuroendocrine cells dissociated from the ventral prostate of rat. Pflugers Arch 2003; 446: 88-99.
33. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001; 12 (Suppl 2): S141-S144.
34. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002; 53: 118-123.
35. Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rosette J et al. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: Cell kinetic features of neuroendocrine cells in the human prostate. Am J Pathol 1997; 151: 1759-1765.
36. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001; 48: 7-15.
37. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-188.
38. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem 2002; 277: 10824-10833.
39. Thebault S, Roudbaraki M, Sydorenko V, Shuba Y, Lemonnier L, Slomianny C et al. alpha1-adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest 2003; 111: 1691-1701.
40. Vanoverberghe K, Mariot P, Vanden Abeele F, Delcourt P, Parys JB, Prevarskaya N. Mechanisms of ATP-induced calcium signaling and growth arrest in human prostate cancer cells. Cell Calcium 2003; 34 75-85.
41. Hajnoczky G, Davies E, Madesh M. Calcium signaling and apoptosis. Biochem Biophys Res Commun 2003; 304: 445-454.
42. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: The calcium-apoptosis link. Nat Rev Mol Cell Biol 2003; 4: 552-565.
43. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ et al. Calcium and apoptosis: Facts and hypotheses. Oncogene 2003; 22: 8619-8627.
44. Lipskaia L, Lompre AM. Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation. Biol Cell 2004; 96: 55-68.
45. Munaron L, Antoniotti S, Lovisolo D. Intracellular calcium signals and control of cell proliferation: How many mechanisms? J Cell Mol Med 2004; 8: 161-168.
46. 2+ signaling. Cell Mol Life Sci 2005; 62: 2405-2413.
47. Parekh AB, Putney Jr JW. Store-operated calcium channels. Physiol Rev 2005; 85: 757-810.
48. Hoth M, Penner R. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 1992; 355: 353-356.
49. Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, Roudbaraki M et al. Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 2002; 1: 169-179.
50. 2+ store to the plasma membrane. Nature 2005; 437: 902-905.
51. 2+ influx. Curr Biol 2005; 15: 1235-1241.
52. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, Tanasa B et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441: 179-185.
53. Pedersen SF, Owsianik G, Nilius B. TRP channels: An overview. Cell Calcium 2005; 38: 233-252.
54. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol 2006: 68: 619-647.
55. 2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells. J Biol Chem 2004; 279: 30326-30337.
56. Vanden Abeele FV, Shuba Y, Roudbaraki M, Lemonnier L, Vanoverberghe K, Mariot P et al. Store-operated Ca(2+) channels in prostate cancer epithelial cells: Function, regulation, and role in carcinogenesis. Cell Calcium 2003; 33: 357-373.
57. 2+ transporter type 1. J Biol Chem 2003; 278 15381-15389.
58. Kahr H, Schindl R, Fritsch R, Heinze B, Hofbauer M, Hack ME et al. CaT1 knock-down strategies fail to affect CRAC channels in mucosal-type mast cells. J Physiol 2004; 557: 121-132.
59. Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM et al. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem 1999; 274: 22739-22746.
60. 2+-selective cation channel TRPV6 in human prostate cancer: A novel prognostic marker for tumor progression. Oncogene 2003; 22: 7858-7861.
61. Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM et al. CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 2001; 282: 729-734.
62. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A et al. Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 2001; 276: 19461-19468.
63. Schwarz EC, Wissenbach U, Niemeyer BA, Strauss B, Philipp SE, Flockerzi V et al. TRPV6 potentiates calcium-dependent cell proliferation. Cell Calcium 2006; 39: 163-173.
64. 2+ current and TRPV6 channels in lymph node prostate cancer cells. J Biol Chem 2003; 278: 50872-50879.
65. Thomas AP, Bird GS, Hajnoczky G, Robb-Gaspers LD, Putney Jr JW. Spatial and temporal aspects of cellular calcium signaling. FASEB J 1996; 10: 1505-1517.
66. 2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 2006; 66: 2038-2047.
67. Kyprianou N, Chon J, Benning CM. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on call proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. Prostate Suppl 2000; 9: 42-46.
68. Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res 2002; 62: 597-602.
69. Pigozzi D, Ducret T, Tajeddine N, Gala JL, Tombel B, Gailly P. Calcium store contents control the expression of TRPC1, TRPC3 and TRPV6 proteins in LNCaP prostate cancer cell line. Cell Calcium 2006; 39: 401-415.
70. 2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 2004; 11: 321-330.
71. 2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun 2004; 322: 1326-1335.
72. McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002; 416: 52-58.
73. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM et al. A TRP channel that senses cold stimuli and menthol. Cell 2002; 108: 705-715.
74. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001; 61: 3760-3769.
75. Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A, Gordienko D et al. Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. J Biol Chem 2005; 280: 39423-39435.
76. 2+ channel required for the survival of prostate cancer cells. Cancer Res 2004; 64: 8365-8373.
77. Bidaux G, Roudbaraki M, Merle C, Crepin A, Delcourt P, Slomianny C et al. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: Functional androgen receptor requirement. Endocr Relat Cancer 2005; 12: 367-382.
78. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34: 251-258.
79. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 2003; 169: 1553-1557.
80. Nantermet PV, Xu J, Yu Y, Hodor P, Holder D, Adamski S et al. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem 2004; 279: 1310-1322.
81. Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M et al. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol 2003; 23: 221-228.
82. Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B et al. Identification of an HLA-A'0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate 2003; 56: 270-279.
83. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
84. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003; 63: 4196-4203.
85. Furst J, Gschwentner M, Ritter M, Botta G, Jakab M, Mayer M et al. Molecular and functional aspects of anionic channels activated during regulatory volume decrease in mammalian cells. Pflugers Arch 2002; 444: 1-25.
86. Okada Y, Shimizu T, Maeno E, Tanabe S, Wang X, Takahashi N. Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. J Membr Biol 2006; 209: 21-29.
87. Shen MR, Yang TP, Tang MJ. A novel function of BCL-2 overexpression in regulatory volume decrease. Enhancing swelling-activated Ca(2+) entry and Cl(-) channel activity. J Biol Chem 2002; 277: 15592-15599.
88. Lemonnier L, Shuba Y, Crepin A, Roudbaraki M, Slomianny C, Mauroy B et al. Bcl-2-dependent modulation of swelling-activated Cl- current and CIC-3 expression in human prostate cancer epithelial cells. Cancer Res 2004; 64: 4841-4848.
89. Shuba YM, Prevarskaya N, Lemonnier L, Van Coppenolle F, Kostyuk PG, Mauroy B et al. Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line. Am J Physiol Cell Physiol 2000; 279: C1144-C1154.
90. 2+ modulation of volume-regulated anion channels: evidence for colocalization with store-operated channels. FASEB J 2002; 16: 222-224.
91. - current associated with neuroendocrine differentiation of prostate cancer epithelial cells. Endocr Relat Cancer 2005; 12: 335-349.
92. Duan D, Winter C, Cowley S, Hume JR, Horowitz B. Molecular identification of a volume-regulated chloride channel. Nature 1997; 390: 417-421.